Healthcare Industry News: Healthpoint
News Release - April 11, 2007
Herbert Slade, MD Joins DFB as Chief Medical Officer and Senior Vice President, Medical AffairsFORT WORTH, Texas, April 11 (HSMN NewsFeed) -- Herbert B. Slade, MD has filled the newly-created position of Chief Medical Officer and Senior Vice President of Medical Affairs for DFB Branded Pharmaceuticals, a segment of Fort Worth-based DFB Pharmaceuticals, Inc., according to Michael E. Steadman, DFB Branded Pharmaceuticals Group President and Chief Operating Officer.
Dr. Slade is a board-certified sub-specialist in clinical immunology with more than 15 years of industry based experience in clinical research. He earned his undergraduate degree in biology from Hamilton College in Clinton, N.Y., followed by his medical degree from State University of New York, Upstate Medical Center in Syracuse, N.Y. Dr. Slade stayed at SUNY to begin his residency in pediatrics, which he completed at C.S. Mott Children's Hospital in Ann Arbor, Mich. His residency was followed by a fellowship in clinical immunology at the University of Michigan, Ann Arbor.
After holding academic appointments at the University of Michigan and Cornell University Medical Center, he left academia to join the pharmaceutical industry. Dr. Slade worked with Jonas Salk, MD on an HIV therapeutic vaccine project at Rhone-Poulenc Rorer and in 1994, left his position there as Director of AIDS and Immunology to join 3M Pharmaceuticals as Director, Worldwide Medical and Scientific Affairs.
"Dr. Slade's experience will enhance DFB's clinical development capability and increase our ability to develop products and therapies to complement our existing wound care, surgical and dermatological portfolios," said Mr. Steadman.
DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes Healthpoint, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for tissue management and surgical indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton's German subsidiary, Phyton GmbH, which operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation. DFB is on the web at http://www.dfb.com .
Source: DFB Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.